Ukrainian Journal of Perinatology and Pediatrics. 2026.1(105): 27-33. doi: 10.15574/PP.2026.1(105).2733
Siracli U. M.
Azerbaijan Medical University, Baku

For citation: Siracli UM. (2026). Relationship between PAPP-A levels, placental morphometric parameters, and perinatal outcomes in pregnant women with fetoplacental insufficiency. Ukrainian Journal of Perinatology and Pediatrics. 1(105): 27-33. doi: 10.15574/PP.2026.1(105).2733.
Article received: Dec 11, 2025. Accepted for publication: Feb 16, 2026.

Fetal growth restriction (FGR) and fetoplacental insufficiency (FPI) are major complications of pregnancy associated with adverse perinatal outcomes. Pregnancy-associated plasma protein A (PAPP-A) and placental morphometry have been proposed as potential predictors of fetal growth and neonatal health.
Aim – to evaluate the relationship between first-trimester PAPP-A, placental morphometry, and neonatal outcomes in pregnancies complicated by FPI and FGR, and to assess their predictive value for monitoring intrauterine growth.
Materials and methods. A prospective cohort study was conducted between 2023 and 2025. The study included 42 deliveries from women aged 20-40 years with FPI and FGR. Maternal and neonatal data were collected. Placental morphometry and PAPP-A were analyzed for correlation with neonatal outcomes. Statistical analyses included mean ± standard deviations, ranges, 95% confidence intervals, t-tests, analysis of variance (ANOVA), and Pearson/Spearman correlation coefficients.
Results. Gestational age ranged from 30⁺⁴ to 40⁺⁶ weeks. Preterm deliveries (<37 weeks) were less frequent and associated with lower birth weight (LBW) and Apgar scores. The mean birth weight was 3280±417 g, mean neonatal length 50.8±2.9 cm, mean placental volume 70.9±36.5 cm³, and mean PAPP-A 0.92±0.70 MoM. Reduced PAPP-A (<0.5 MoM) was associated with LBW (<2900 g) and smaller placental volume, whereas elevated PAPP-A (>1.5 MoM) corresponded to higher birth weight (>3700 g) and larger placental volume. PAPP-A positively correlated with birth weight and placental volume. Increased placental volume was also associated with greater neonatal length and mass.
Conclusion. PAPP-A levels and placental morphometric characteristics are significant predictors of fetal growth and neonatal outcomes in pregnancies complicated by FPI and FGR.
The research was carried out in accordance with the principles of the Declaration of Helsinki. The informed consent of the patients was obtained for conducting the studies.
The author declares the absence of conflict of interests.
Keywords: pregnancy-associated plasma protein A (PAPP-A), placental volume, fetal growth restriction, fetoplacental insufficiency, neonatal outcomes.

REFERENCES

1. Conover CA. (2024, Dec). Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular disease. Growth Horm IGF Res. 79: 101625. https://doi.org/10.1016/j.ghir.2024.101625; PMid:39419664

2. Garcia-Manau P, Bonacina E, Martin-Alonso R et al. (2025). Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label randomized controlled trial. Nat Med. 31: 1008-1015. https://doi.org/10.1038/s41591-024-03421-9; PMid:39775039

3. Huang H, Wang S. (2025. Sep 3). Prediction of Fetal Growth Restriction Using Serum PlGF Combined with PAPP-A in Early Pregnancy. Int J Womens Health. 17: 2845-2851. https://doi.org/10.2147/IJWH.S524412; PMid:40927559 PMCid:PMC12415620

4. Ignatko IV, Bogomazova IM, Kardanova MA. (2023). Current views on the diagnosis and prognosis of fetal growth restriction: a literature review. J Obstet Womens Dis. 72(3): 65-76. https://doi.org/10.17816/JOWD344442

5. Khalafli K, Tagieva F, Ragimov D, Rustamova L, Dzhafarova H et al. (2025). Regional features of birth rate dynamics in Azerbaijan. Azerb Med J. (1): 122-126. https://doi.org/10.34921/amj.2025.1.021

6. Li Y, Meng Y, Chi Y, Li P, He J. (2023, Nov 24). Meta-analysis for the relationship between circulating pregnancy-associated plasma protein A and placenta accreta spectrum. Medicine (Baltimore). 102(47): e34473. https://doi.org/10.1097/MD.0000000000034473; PMid:38013313 PMCid:PMC10681609

7. Monget P, Oxvig C. (2016, Jun). PAPP-A and the IGF system. Ann Endocrinol (Paris). 77(2): 90-96. https://doi.org/10.1016/j.ando.2016.04.015; PMid:27155776

8. Palmrich P, Kalafat E, Pateisky P, Schirwani-Hartl N, Haberl C, Herrmann C et al. (2024, May). Prognostic value of angiogenic markers in pregnancy with fetal growth restriction. Ultrasound Obstet Gynecol. 63(5): 619-626. https://doi.org/10.1002/uog.27509; PMid:37774098

9. Shinohara S, Sunami R, Yasuda G, Kasai M. (2026). sFlt-1/PlGF ratio predicts serious outcomes in early-onset fetal growth restriction. Fetal Diagn Ther. 53(1): 32-42. https://doi.org/10.1159/000547695; PMid:40825317

10. Shu Z, Wang W. (2025). Predictive value of prenatal screening markers combined with serum placental growth factor in early pregnancy for preeclampsia. Pak J Med Sci. 41(2): 598-602. https://doi.org/10.12669/pjms.41.2.9794; PMid:39926691 PMCid:PMC11803793

11. Villalaín C, Galindo A, D'Antonio F, Herraiz I. (2025, Dec) Clinical use of angiogenesis biomarkers in fetal growth restriction: a narrative review. J Matern Fetal Neonatal Med. 38(1): 2589630. Epub 2025 Nov 23. https://doi.org/10.1080/14767058.2025.2589630; PMid:41276305

12. Wang F, Chen S, Wang J, Wang Y, Ruan F, Shu H et al. (2021, Mar). First trimester serum PAPP-A is associated with placenta accreta: a retrospective study. Arch Gynecol Obstet. 303(3): 645-652. https://doi.org/10.1007/s00404-020-05960-1; PMid:33515274